A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Inclusion Criteria: * Males, between 18 and 55 years of age, inclusive * Body Mass Index range 18.0 to 30.0 kg/m2, inclusive * Have NAT2 slow or rapid acetylator genotype * In good health as determined by the investigator * Negative test for selected drugs of abuse at screening * Negative screens for Hepatitis B, Hepatitis C and HIV * Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge * Able to comprehend and willing to sign an Informed Consent Form * Have 1 to 2 bowel movements per day Exclusion Criteria: * Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance * History of stomach or intestinal surgery or resection * History or presence of an abnormal ECG, * History of clinically significant alcohol or drug use within 1 year prior to Check-in * Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in * Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in * Use of any drugs which may interact with the study drug within 30 days prior to Check-in * Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in * Use of any prescription medications/products within 14 days prior to Check in * Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in * Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in * Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in * Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion * Receipt of blood products within 2 months prior to Check-in * Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study